Clinical practice guidelines recommend target serum levels for phosphorus, calcium and parathyroid hormone in patients with chronic kidney disease. However, a recent meta-analysis has found that only levels of phosphorus seem to be associated with the risk of death in these patients.
This is a preview of subscription content, log in via an institution to check access.
References
Palmer, S. C. et al. Serum levels of phosphorus, parathyroid hormone, and calcium and risks of death and cardiovascular disease in individuals with chronic kidney disease: a systematic review and meta-analysis. JAMA 305, 1119–1127 (2011).
Dhingra, R. et al. Relations of serum phosphorus and calcium levels to the incidence of cardiovascular disease in the community. Arch. Intern. Med. 167, 879–885 (2007).
Singh, A. K. et al. Correction of anemia with epoetin alfa in chronic kidney disease. N. Engl. J. Med. 355, 2085–2098 (2006).
Veritas Medicine Clinical Study Report PR00-06-014 (CHOIR) [online], (2006).
Phrommintikul, A., Haas, S. J., Elsik, M. & Krum, H. Mortality and target haemoglobin concentrations in anaemic patients with chronic kidney disease treated with erythropoietin: a meta-analysis. Lancet 369, 381–388 (2007).
Palmer, S. C. et al. Meta-analysis: erythropoiesis-stimulating agents in patients with chronic kidney disease. Ann. Intern. Med. 153, 23–33 (2010).
Miskulin, D. et al. Key comorbid conditions that are predictive of survival among hemodialysis patients. Clin. J. Am. Soc. Nephrol. 4, 1818–1826 (2009).
Author information
Authors and Affiliations
Ethics declarations
Competing interests
The author declares no competing financial interests.
Rights and permissions
About this article
Cite this article
Foley, R. Levels of phosphorus and patient outcomes. Nat Rev Nephrol 7, 428–430 (2011). https://doi.org/10.1038/nrneph.2011.87
Published:
Issue Date:
DOI: https://doi.org/10.1038/nrneph.2011.87
- Springer Nature Limited